Neurim Pharmaceuticals Ltd., of Tel Aviv, Israel, granted Biocodex exclusive rights to market its investigational pediatric melatonin drug, Rx Pedprm, in France. The drug is targeted to treat sleep disorders in children with autism spectrum disorders and neurogenetic diseases.